Teva Pharmaceutical Industries Ltd. May 23 announced that the Food and Drug Administration has approved the use of QVAR (beclomethasone dipropionate HFA) with a dose counter for the ongoing treatment of asthma in patients 5 years and older.
The dose counter is designed to help asthma patients, as well as their caregivers, keep track of the number of doses remaining in the canister, the Israel-based company said. The new product will be commercially available later in 2014.
QVAR is an inhaled corticosteroid (ICS) recommended as a twice-daily treatment for long-term asthma control, Teva said. Adherence to daily control medications, like ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.